UCB SA Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/23/2026)
| Balance Sheet | Total Assets | 18,158,000,000.00 | ROE | 59.85 % |
| Balance Sheet | Total Equity | 10,867,000,000.00 | ROA | 8.58 % |
| Cashflow | Capital Expenditures | -281,000,000.00 | P/FCF | 20.39 |
| Cashflow | Free Cash Flow | 1,882,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 2,163,000,000.00 | P/CF | 17.74 |
| Income | Earnings per Share (diluted) | 8.20 | Div. Yield | 0.72 % |
| Income | Net Income | 1,558,000,000.00 | P/E | 24.63 |
| Income | Shares Outstanding | 190,000,000.00 | P/B | 3.53 |
| Income | Total Revenue | 7,741,000,000.00 | P/S | 4.96 |
Ratios calculated on: 10/14/2026
Company Description
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.ucb.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more